Literature DB >> 8567207

Why is the pharmaceutical industry investing increasing amounts in health economic evaluations?

F Andersson.   

Abstract

Over the last few years, the pharmaceutical industry has financed an increasing number of health economic evaluations. The purpose of this article is to describe how and why the pharmaceutical industry is applying health economic evaluations. Seven different fields of application are identified, and the varying reasons for use are discussed.

Mesh:

Substances:

Year:  1995        PMID: 8567207     DOI: 10.1017/s0266462300009181

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  4 in total

1.  Health economics in the Canadian pharmaceutical industry.

Authors:  L Assiff; M R Pollock; P Manzi; B Faienza; D Menon
Journal:  Pharmacoeconomics       Date:  1999-12       Impact factor: 4.981

2.  The Danish approach to standards for economic evaluation methodologies.

Authors:  A Alban; M Gyldmark; A V Pedersen; J Søgaard
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

Review 3.  Common errors and controversies in pharmacoeconomic analyses.

Authors:  S Byford; S Palmer
Journal:  Pharmacoeconomics       Date:  1998-06       Impact factor: 4.981

4.  An economic model of 2-hour post-dose ciclosporin monitoring in renal transplantation.

Authors:  Paul A Keown; Bryce Kiberd; Robert Balshaw; Shideh Khorasheh; Carlo Marra; Philip Belitsky; Zoltan Kalo
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.